New inflammation hormone link may pave way to study new drugs for Type 2 diabetes

A new link between obesity and type 2 diabetes found in mice could open the door to exploring new potential drug treatments for diabetes, University of Michigan Health System research has found.

Drugs for type 2 diabetes commonly , which lowers . But the U-M study suggests that – a pancreas-produced hormone that has the opposite effect of insulin by raising blood glucose levels – may also provide a powerful pathway to preventing and treating the increasingly prevalent disease.

Findings of the study were published this week ahead of print in Nature Medicine.

"Reducing sugar levels is the biggest goal for people with type 2 diabetes," says senior author Liangyou Rui, Ph.D., associate professor in the Department of Molecular and Integrative Physiology at the U-M Medical School. "We've mostly focused on controlling insulin production and action to treat diabetes but there has been very little study on the opposite hormone glucagon.

"Our study shows for the first time that obesity also affects glucagon action and that this hormone also contributes to high glucose levels found in type 2 diabetes."

Authors identified the NIK/NF-B2 pathway, which promotes glucagon responses in obesity. NIK was abnormally activated in with dietary or genetic obesity and the inhibition of liver NIK was found to cure diabetes in obese mice.

Insulin resistance – which reduces the body's ability to decrease blood glucose – has been the main hallmark of type 2 diabetes, which is the most common form of diabetes in the United States afflicting millions of Americans.

"There is a common theory that inflammation in liver and fat tissue associated with obesity causes insulin resistance and that leads to the biggest problem for type 2 diabetes: high blood glucose levels," Rui says.

"But blood glucose is also controlled by this other hormone glucagon, which signals to the liver to produce glucose. Inflammation may enhance the ability of glucagon to increase blood sugar.

" is a growing problem worldwide, leading to more cases of ," Rui adds. "We hope to offer more data that can help expand options to treat this rampant disease."

Related Stories

Study pinpoints role of insulin on glucagon levels

Apr 07, 2009

April 7, 2009 - Researchers at the Joslin Diabetes Center have shown for the first time that insulin plays a key role in suppressing levels of glucagon, a hormone involved in carbohydrate metabolism and regulating blood glucose ...

Recommended for you

Economic burden of prediabetes up 74 percent over five years

Nov 20, 2014

The economic burden of diabetes in America continues to climb, exceeding more than $322 billion in excess medical costs and lost productivity in 2012, or more than $1,000 for every American, according to a study being published ...

Gynoid fat resists metabolic risks of obesity

Nov 19, 2014

(HealthDay)—The differences in the developmental profiles of upper-body and lower-body fat depots may explain their opposing associations with obesity-related metabolic disease, according to research published ...

Treating diabetes one meal at a time

Nov 19, 2014

Recent estimates project that as many as one in three American adults will have diabetes in 2050. The American Diabetes Association observes November as American Diabetes Month, and this year's theme is America ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.